Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974771 | 0.91 | KMT2A (0.47) | KMT2AGBA1NPY5RPOLBMEN1 | |
| SCHEMBL19975337 | 0.85 | KMT2A (0.54) | KMT2AGBA1NPY5RPOLBMEN1 | |
| SCHEMBL19975436 | 0.80 | KMT2A (0.48) | KMT2AGBA1NPY5RPOLBMEN1 | |
| SCHEMBL19975371 | 0.78 | CTSL (0.46) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21176234 | 0.77 | GBA1 (0.49) | KMT2AGBA1NPY5RPOLBMEN1 | |
| SCHEMBL19974744 | 0.75 | KMT2A (0.64) | KMT2ANPY5RPOLBMEN1ALDH1A1 | |
| SCHEMBL19975409 | 0.74 | GBA1 (0.51) | KMT2AGBA1NPY5RPOLBMEN1 | |
| SCHEMBL19975045 | 0.74 | KMT2A (0.42) | KMT2AGBA1POLBMEN1ALDH1A1 | |
| SCHEMBL21176298 | 0.74 | KMT2A (0.52) | KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19974908 | 0.74 | KMT2A (0.52) | KMT2ANPY5RMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | KMT2A 4031/4885GBA1 68/4885NPY5R 4477/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | KMT2A 4177/4885GBA1 81/4885NPY5R 4656/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | KMT2A 4031/4885GBA1 68/4885NPY5R 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.